FDA approves Alvotech and Teva’s SELARSDI for new indications
The FDA has approved a new presentation of Alvotech and Teva’s SELARSDI, for the treatment of ulcerative colitis and Crohn's disease.
The FDA has approved a new presentation of Alvotech and Teva’s SELARSDI, for the treatment of ulcerative colitis and Crohn's disease.
What's Your Reaction?
